Enanta Pharmaceuticals, Inc. — Form 10-Q Summary
Reporting period: Fiscal second quarter and six months ended March 31, 2017. Financial amounts below are in millions of dollars unless stated otherwise.
Business context
Enanta is a research-and-development-focused biotechnology company. Its royalty revenue is primarily tied to AbbVie’s hepatitis C (HCV) regimens containing Enanta-discovered protease inhibitors. Its wholly owned programs focus on NASH, primary biliary cholangitis (PBC), respiratory syncytial virus (RSV), and hepatitis B (HBV).
Financial results and liquidity
| Metric | Three months ended Mar. 31, 2017 | Six months ended Mar. 31, 2017 |
|---|---|---|
| Revenue | $9.0 | $19.4 |
| Operating expenses | $18.5 | $35.9 |
| Operating income (loss) | $(9.5) | $(16.6) |
| Net income (loss) | $(5.4) | $(10.4) |
| Operating margin | Approximately (106)% | Approximately (85)% |
- Quarterly revenue consisted entirely of AbbVie royalties: $9.0 million, down from $13.0 million a year earlier. The six-month total was $19.4 million, versus $61.4 million in 2016.
- Six-month 2017 results included a $5.1 million income tax benefit; the comparable 2016 period included $30.0 million of AbbVie milestone revenue and $0.6 million under the NIAID contract, neither of which recurred in 2017.
- Research and development expense rose to $25.5 million for six months from $18.2 million, reflecting increased clinical and preclinical activity, headcount, and external costs. General and administrative expense increased to $10.4 million from $8.2 million, primarily due to stock-based compensation.
- Six-month operating cash flow was $0.1 million, compared with $40.0 million provided in the prior-year period. Cash and cash equivalents increased by $2.6 million to $19.2 million; cash, cash equivalents, and marketable securities totaled $240.9 million.
- At March 31, 2017, total assets were $279.0 million and total liabilities were $12.9 million. Enanta reported no debt other than capital lease obligations; these were $0.5 million in total. Current assets were $190.6 million and current liabilities $9.2 million.
Material changes and outlook
- Lower paritaprevir royalties reflected declining AbbVie HCV regimen sales amid increased competition. The prior-year six-month comparison also benefited from the $30.0 million Japan approval milestone.
- AbbVie’s glecaprevir/pibrentasvir (G/P) combination was under regulatory review in the U.S., E.U., and Japan. Enanta could receive up to $80 million in approval milestones and, if commercialized, tiered double-digit royalties on an agreed share of net sales.
- Enanta reported EDP-305 in Phase 1 and planned to study it in PBC patients in Q4 2017, with a NASH patient study targeted to begin in 2018. EDP-305 had received FDA Fast Track designation for NASH with liver fibrosis. The company planned to begin a Phase 1 study of RSV candidate EDP-938 in Q4 2017 and aimed to identify an HBV development candidate in 2017.
- Management said existing financial resources and expected cash flows should fund operations for the foreseeable future, while noting that funding needs depend on collaboration revenue, program progress, trial costs, and other factors. No specific earnings or revenue guidance was provided.
- Key risks include reliance on AbbVie’s development and commercialization decisions and HCV sales; competitive and pricing pressure; regulatory, clinical, and safety uncertainties; and the possibility that additional financing may be needed if revenue or development outcomes fall short. Management reported effective disclosure controls and no material change in internal control over financial reporting.
- The filing reported no pending or threatened litigation and no material changes in commitments and contingencies during the six months.
Important facts for investors to verify
- AbbVie’s latest HCV sales, market share, pricing, and the resulting royalty trends for Enanta.
- Regulatory decisions and launch timing for G/P, and the likelihood and timing of any related milestones and royalties.
- Progress, timelines, and spending for EDP-305, EDP-938, and the HBV program, including whether stated study targets are met.
- Cash burn and liquidity runway as research and clinical spending increases, and the assumptions behind management’s “foreseeable future” assessment.
- The impact of the tax benefit and nonrecurring prior-year milestone revenue when comparing reported earnings across periods.